Verified July 2026 · Cited to primary sources
Semaglutide: Evidence Grade A. FDA-approved / proven in humans.
The honest verdict
Grade A, and the reference standard for medical weight loss. If you qualify, the science is settled: real, sustained loss plus a cardiovascular benefit that few weight interventions can claim. We grade the molecule here and hand off the shopping. For provider comparison, telehealth options, and where to actually get semaglutide, go to glp1picks.com, our sister site built specifically for that.
Semaglutide at a glance
- Class
- GLP-1 receptor agonist
- Mechanism
- A long-acting analog of glucagon-like peptide-1 (GLP-1). It binds GLP-1 receptors in the pancreas, brain, and gut to boost glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite through central satiety signaling. The 2.4 mg weekly dose is what drives the weight-loss effect; lower doses are used for type 2 diabetes.
- Also known as
- Wegovy, Ozempic, Rybelsus, NN9535
- Research applications
- Chronic weight management
- Type 2 diabetes glycemic control
- Cardiovascular risk reduction in established disease
- Forms
- Subcutaneous injection (weekly pen), Oral tablet (daily, diabetes indication)
- Legal status
- FDA-approved
- WADA (anti-doping)
- Not on the WADA Prohibited List (2025). GLP-1 agonists are not classified as performance-enhancing, though rapid weight loss has body-composition implications for weight-class athletes.
- Evidence grade
- Grade AFDA-approved / proven in humans
How we grade evidence
Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is Semaglutide?
The once-weekly GLP-1 that turned obesity into a treatable condition, with roughly 15 percent average body-weight loss in its landmark trial and a proven cardiovascular benefit on top.
A long-acting analog of glucagon-like peptide-1 (GLP-1). It binds GLP-1 receptors in the pancreas, brain, and gut to boost glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite through central satiety signaling. The 2.4 mg weekly dose is what drives the weight-loss effect; lower doses are used for type 2 diabetes.
How strong is the evidence for Semaglutide?
FDA-approved for chronic weight management and type 2 diabetes, backed by multiple large phase 3 randomized controlled trials. STEP 1 showed a mean 14.9 percent body-weight reduction at 68 weeks versus 2.4 percent on placebo. SELECT, a 17,604-patient cardiovascular outcomes trial, showed a 20 percent relative reduction in major cardiac events. This is as strong as human evidence gets for a peptide.
Primary sources (2)
Is Semaglutide legal? (Status July 2026)
Prescription via a licensed provider.
What is Semaglutide used for?
Semaglutide is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.
What does Semaglutide cost, and how do you access it legally?
Typical cost
Varies widely by source and coverage
Brand and compounded pricing shift constantly with supply and insurance. We do not quote provider prices here. For current provider pricing and where to get it, see our sister site glp1picks.com.
How to access it legally
Semaglutideis FDA-approved, so the legal route is a prescription from a licensed provider, not a research vial. We don't currently have a vetted partner to link for it, so there's no button here. Ask a licensed clinician about the branded product. We never point you to gray-market or compounded off-label sources.
Trying to lose weight?
For weight loss, an approved GLP-1 beats this peptide.
No research peptide here has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the options that actually work.
Is Semaglutidesafe? Side effects & risks
Well-characterized across tens of thousands of patients. The most common effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst during dose escalation. It carries a boxed warning for thyroid C-cell tumors based on rodent data (contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2). Watch for pancreatitis, gallbladder disease, and dehydration-related kidney injury. Not for use in pregnancy.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
Semaglutide FAQ
How much weight will I actually lose on semaglutide?
In the STEP 1 trial, participants lost an average of 14.9 percent of body weight over 68 weeks at the 2.4 mg dose, and 86 percent lost at least 5 percent. Individual results vary with dose, diet, and whether you stay on it. Weight tends to return after stopping.
Where should I get semaglutide and what does it cost?
That is exactly what our sister site handles. We grade the science here; for a live comparison of providers, prescription pathways, and current pricing, see glp1picks.com.
Is semaglutide safe long term?
It is one of the best-studied peptides in existence, with multi-year safety data from trials like SELECT. The main caveats are the boxed thyroid C-cell warning, ongoing GI effects, and rare pancreatitis or gallbladder events. It should be run under medical supervision, not self-sourced.
From our portfolio
Tracking Semaglutide?
Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.
Keep reading
MOTS-c
An "exercise-mimetic" metabolic peptide. Real mechanistic interest, but human evidence is association-only.
Grade ATesamorelin
One of only two FDA-approved peptides in this space. Proven to cut visceral fat, but approved for a narrow HIV indication.
Grade BRetatrutide
The next-generation weight-loss peptide with the strongest efficacy signal. But it is investigational and not yet available by any legal route.
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.